Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by gregoooon Feb 28, 2012 3:42pm

213 Views

Post# 19600180

RJ trading

Time ET	Ex	Price	Change	Volume	Buyer	Seller	Markers
15:15:50	V	0.075		400	89 Raymond James	85 Scotia	E
15:09:34	V	0.08		500	7 TD Sec	89 Raymond James	E
14:30:50	V	0.075		500	89 Raymond James	25 Odlum	E
11:45:45	V	0.075		500	89 Raymond James	33 Canaccord	E
09:30:00	V	0.08		500	2 RBC	89 Raymond James	E